Study to Evaluate the Effects of Colesevelam on Insulin Sensitivity and ß-Cell Function in Subjects With Impaired Fasting Glucose (Prediabetes)

Inclusion Criteria: * Males or females (postmenopausal, surgically sterile or using double-barrier method of contraception), aged 18-75 years, FPG 100-115 mg/dl at screening (average of 2 measurements during screening; no individual measurement outside of the range 92-125 mg/dl) * In good health as determined by past medical history, physical examination, electrocardiogram, laboratory tests and urinalysis * HbA1c \<6.5% at screening * Body mass index (BMI) in the range of 22-40 kg/m2 inclusive and with a stable (+/-2.5 kg) weight for the last 6 months * Subjects must be willing to: * Maintain prior exercise and dietary habits throughout the study * Comply with all study requirements * Provide written informed consent Exclusion Criteria: * Pregnant or lactating females * Patients diagnosed with type 2 diabetes or that have taken glucose-lowering agents or insulin, except during pregnancy * Chronic oral or parenteral corticosteroid treatment (\>7 consecutive days of treatment) within 8 weeks prior to screening * HIV protease inhibitors * Warfarin or phenytoin use * Triglycerides \>500 mg/dl * History of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection * History of dysphagia, swallowing disorders or intestinal motility disorder * History of pancreatitis * Uncontrolled hypothyroidism * Individuals with clinical hepatic disease or liver function tests greater than ≥2 times upper limits of normal within 30 days preceding the first dose of study drug * On a weight loss program with ongoing weight loss, or starting an intensive exercise program within 4 weeks of study initiation * Current or prior (within the past 3 months) treatment with a bile acid sequestrant (colesevelam, colestipol, colestimide, or cholestyramine) * Use of any investigational drug in the last 30 days * Donation of one unit (500 ml) or more of blood, significant blood loss equaling at least one unit of blood within the past 2 weeks or a blood transfusion within 8 weeks prior to screening * Employment by the research center